Cargando…

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

Detalles Bibliográficos
Autores principales:	Sanz-Caballer, J., Storek, J., Socié, G., Thirumalai, D., Guzman-Beccera, N., Xun, P., Kumar, D., Sadetsky, N., Dierickx, D., Reitan, J., Barlev, A., Mohty, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431261/ http://dx.doi.org/10.1097/01.HS9.0000848220.74181.5a

Ejemplares similares

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Dharnidharka, V., et al.
Publicado: (2022)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study
por: Chaganti, Sridhar, et al.
Publicado: (2023)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES
por: Choquet, S., et al.
Publicado: (2022)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
por: Kris Michael, Mahadeo, et al.
Publicado: (2023)

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
por: Choquet, Sylvain, et al.
Publicado: (2023)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient
por: Afshar, Kamyar, et al.
Publicado: (2011)

AGREEMENT CERN No. K 1339
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2006)

ACCELERATION OF HEPATIC CHOLESTEROL SYNTHESIS BY TRITON WR-1339
por: Frantz, Ivan D., et al.
Publicado: (1955)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment
por: Li, Xiaofan, et al.
Publicado: (2015)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

THE MECHANISM RESPONSIBLE FOR THE HYPERCHOLESTEREMIA INDUCED BY TRITON WR-1339
por: Friedman, Meyer, et al.
Publicado: (1953)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis
por: Stravodimou, A., et al.
Publicado: (2012)

P1346: EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT
por: Kissane, E., et al.
Publicado: (2022)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

1339. Impact of COVID-19 Pandemic on Activity of Other Respiratory Viral Pathogen and Norovirus
por: DiBiase, Lauren, et al.
Publicado: (2021)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis
por: Kuhlman, Justin J., et al.
Publicado: (2021)

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
por: Pimm, M. V., et al.
Publicado: (1975)

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
por: Heffeter, Petra, et al.
Publicado: (2013)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

Late Onset Graft Plasmacytoma-Like PTLD Presenting as Acute Hyperglycemia in a Kidney-Pancreas Transplant Recipient
por: Ventura-Aguiar, P., et al.
Publicado: (2019)

Understanding celiac disease monitoring patterns and outcomes after diagnosis: A multinational, retrospective chart review study
por: Lundin, Knut EA, et al.
Publicado: (2021)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

EBV Infection in XLP1 Manifested Solely by Behavioral Aggression and Effective Treatment Using Rituximab
por: Korah-Sedgwick, Michelle M., et al.
Publicado: (2018)

STUDIES ON THE EFFECT OF TRITON (WR-1339) ON GUINEA PIG TISSUES : II. FRAGILITY OF BLOOD CELLS
por: Hudgins, Paul C., et al.
Publicado: (1958)

1339. Impact of Implementing Procalcitonin Testing with Comprehensive Education on Procalcitonin Ordering Habits and Antibiotic Usage
por: Johnsrud, Joyce, et al.
Publicado: (2019)

RC1339/APRc from Rickettsia conorii Is a Novel Aspartic Protease with Properties of Retropepsin-Like Enzymes
por: Cruz, Rui, et al.
Publicado: (2014)

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
por: Rausch, Lisa, et al.
Publicado: (2016)

Targeted Therapy with Rituximab in Felty’s Syndrome: A Case Report
por: Heylen, Line, et al.
Publicado: (2012)

Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series
por: Horovitz, Dafne Dain Gandelman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l5d6brve6qnq9mi4a08te4hb9i